Compare CYCU & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYCU | MRKR |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 16.6M |
| IPO Year | N/A | N/A |
| Metric | CYCU | MRKR |
|---|---|---|
| Price | $2.43 | $2.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $10.17 |
| AVG Volume (30 Days) | 147.3K | ★ 547.5K |
| Earning Date | 02-24-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,667,874.00 | $4,694,988.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.13 | $0.81 |
| 52 Week High | $2,028.87 | $4.07 |
| Indicator | CYCU | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 38.52 | 63.59 |
| Support Level | $2.29 | $1.93 |
| Resistance Level | $2.91 | $2.29 |
| Average True Range (ATR) | 0.25 | 0.26 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 17.90 | 60.92 |
Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.